Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: Where antibody imaging dares to tread

Journal of Nuclear Medicine

Volumn 55, Issue 5, 2014, Pages 708-709

  Marquez, Bernadette V ^a   Zheleznyak, Alexander ^a   Lapi, Suzanne E ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM GLYPICAN 3 MONOCLONAL ANTIBODY ZR 89;

ANTIBODY SPECIFICITY; BIOACCUMULATION; BIOLUMINESCENCE; CANCER MODEL; CONTRAST ENHANCEMENT; DRUG LIVER LEVEL; DRUG TUMOR LEVEL; HISTOPATHOLOGY; HUMAN; INTERNALIZATION; ISOTOPE LABELING; LIVER CELL CARCINOMA; MOLECULAR IMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; HUMANS; LIVER NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; ZIRCONIUM;

EID: 84901345189     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.136234     Document Type: Short Survey

References (26)

1. Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
2. Lan Y, Ge J, Zhuo Y, Wang J, Chen H, Liu H. Construction of the enhanced yellow fluorescent protein expression vector carrying IFN-gamma gene. Yan Ke Xue Bao. 2001;17:154-157.
3. Ding T, Li L, Zhu K, Huang W, Yang Y. Relationship between the increase of secretion of sTNF alpha induced by lipopolysaccharides and the enhanced expression of TACE mRNA in HL-60 cells and adhesive cells from human spleen. J Tongji Med Univ. 2001;21:265-268, 279.
4. Zhu YG, Zhuo GS, Chen ZZ, Chen XC. Cationic lipids enhanced cellular uptake and activity of bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells. Acta Pharmacol Sin. 2001;22:1007-1012.
5. Nayak TK, Garmestani K, Milenic DE, BrechbielMW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med. 2012;53:113-120.
6. Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
7. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
8. Nagengast WB, de Korte MA, Oude Munnink TH, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010;51:761-767.
9. Gaykema SB, Brouwers AH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54:1014-1018.
10. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51: 1293-1300.
11. Janjigian YY, Viola-Villegas N, Holland JP, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013;54:936-943.
12. Sham JG, Kievit FM, Grierson JR, et al. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med. 2014;55:799-804.
13. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011-1018.
14. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001;48:558-564.
15. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12:241-247.
16. Ikotun OF, Marquez BV, Huang C, et al. Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET. PLoS ONE. 2013;8:e77476.
17. van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, et al. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res. 2012;18:6306-6314.
18. Oude Munnink TH, Tamas KR, Lub-de Hooge MN, et al. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441. J Nucl Med. 2013;54:929-935.
19. Chang AJ, Desilva R, Jain S, Lears K, Rogers B, Lapi S. 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals (Basel). 2012;5:79-93.
20. Sugyo A, Tsuji AB, Sudo H, et al. Evaluation of 89Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. PLoS ONE. 2013;8:e61230.
21. Kim KA, Kim MJ, Choi JY, et al. Detection of recurrent hepatocellular carcinoma on postoperative surveillance: comparison of MDCT and gadoxetic acid-enhanced MRI. Abdom Imaging. January 3, 2014 [Epub ahead of print].
22. Kanata N, Yoshikawa T, Ohno Y, et al. HCC-toliver contrast on arterial-dominant phase images of EOB-enhanced MRI: comparison with dynamic CT. Magn Reson Imaging. 2013;31:17-22.
23. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
24. Vlachaki MT, Chhikara M, Aguilar L, et al. Enhanced therapeutic effect of multiple injections of HSV-TK 1 GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys. 2001;51:1008-1017.
25. Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014;588:377-382.
26. Osborne JR, Green DA, Spratt DE, et al. A prospective pilot study of 89Zr-J591/PSMA positron emission tomography (PET) in men with localized prostate cancer undergoing radical prostatectomy. J Urol. October 14, 2013 [Epub ahead of print].